The July 23, 2026, Pharmacy Compounding Advisory Committee meeting produced the main recent catalyst, with an 8-6 vote (one abstention) recommending BPC-157 for the 503A Bulks List despite FDA staff opposition citing immunogenicity and peptide quality risks. This non-binding advisory outcome followed the substance’s earlier removal from Category 2 in April 2026 and placed it in a regulatory gray zone pending agency action. Full movement to Category 1 status still requires FDA acceptance of the recommendation, followed by proposed rulemaking, a public comment period, and a final rule before legal compounding under Section 503A becomes permitted. No final FDA decision has been announced as of mid-August 2026, leaving the timeline dependent on agency priorities and any further procedural developments.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-updateBAGO
Aug 31, 2026
August 31, 2026
13%
December 31, 2026
55%
$2,648 Vol.
August 31, 2026
$942 Vol.
13%
December 31, 2026
$1,706 Vol.
55%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 23, 2026, Pharmacy Compounding Advisory Committee meeting produced the main recent catalyst, with an 8-6 vote (one abstention) recommending BPC-157 for the 503A Bulks List despite FDA staff opposition citing immunogenicity and peptide quality risks. This non-binding advisory outcome followed the substance’s earlier removal from Category 2 in April 2026 and placed it in a regulatory gray zone pending agency action. Full movement to Category 1 status still requires FDA acceptance of the recommendation, followed by proposed rulemaking, a public comment period, and a final rule before legal compounding under Section 503A becomes permitted. No final FDA decision has been announced as of mid-August 2026, leaving the timeline dependent on agency priorities and any further procedural developments.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Binuksan ang Market: Jun 22, 2026, 10:10 PM ET
Volume
$2,648Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The July 23, 2026, Pharmacy Compounding Advisory Committee meeting produced the main recent catalyst, with an 8-6 vote (one abstention) recommending BPC-157 for the 503A Bulks List despite FDA staff opposition citing immunogenicity and peptide quality risks. This non-binding advisory outcome followed the substance’s earlier removal from Category 2 in April 2026 and placed it in a regulatory gray zone pending agency action. Full movement to Category 1 status still requires FDA acceptance of the recommendation, followed by proposed rulemaking, a public comment period, and a final rule before legal compounding under Section 503A becomes permitted. No final FDA decision has been announced as of mid-August 2026, leaving the timeline dependent on agency priorities and any further procedural developments.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,648Petsa ng Pagtatapos
Dec 31, 2026Binuksan ang Market
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The July 23, 2026, Pharmacy Compounding Advisory Committee meeting produced the main recent catalyst, with an 8-6 vote (one abstention) recommending BPC-157 for the 503A Bulks List despite FDA staff opposition citing immunogenicity and peptide quality risks. This non-binding advisory outcome followed the substance’s earlier removal from Category 2 in April 2026 and placed it in a regulatory gray zone pending agency action. Full movement to Category 1 status still requires FDA acceptance of the recommendation, followed by proposed rulemaking, a public comment period, and a final rule before legal compounding under Section 503A becomes permitted. No final FDA decision has been announced as of mid-August 2026, leaving the timeline dependent on agency priorities and any further procedural developments.
Eksperimental na AI-generated summary na nire-reference ang Polymarket data. Hindi ito trading advice at wala itong papel sa kung paano nire-resolve ang market na ito. · Na-update
Mag-ingat sa mga external link.
Mag-ingat sa mga external link.
Mga Madalas na Tanong